We found that the specific ALDH2 inhibitors diadzin and CVT-10216 significantly inhibit ALDH activity in a dose-dependent manner and sensitize AML cells to chemotherapy, even in the presence of MSCs. Here, ALDH2 is linked to acute myeloid leukemia.